Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list - 2The most effective method to Keep up with Proficient Handshakes in a Computerized World
- 3What's going on with Katseye? The Manon Bannerman hiatus drama, explained.
- 4Gulf of Mexico oil spill spread hundreds of miles, killed wildlife and polluted Mexican reserves
- 5Dominating Capable Mastercard Utilization: Key Contemplations
- Savvy Cleaning: The 6 Robot Vacuums of 2024
- A definitive Manual for the Over-Ear Earphones
- Top Fascinating Organic products: Which One Might You Want to Attempt?
- 'Harmonious' meeting between Merz, Lula despite Belém controversy
- The Best Cell phone Brands for Tech Lovers
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- Mexico says a third of 130,000 missing people might be alive, fueling criticisms by families
- UN rights chief: Israel's new Gaza aid agency rules 'outrageous'
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
